Seres Therapeutics Oral Microbiome Product SER-109 for Recurrent C. Difficile Infection Meets Trial Endpoint

• SER-109 demonstrated a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared to placebo.
• Efficacy results Support BLA filing as a single pivotal trial.
• The Company will meet with the FDA to discuss filing for product approval as soon as possible.
• Positive SER-109 Phase 3 data provide validation for the Seres microbiome therapeutics platform and further development of its pipeline of product candidates.
• SER-109 was . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Impacting News

  Seres Therapeutics (MCRB)

  August 10, 2020
  Tweet Pin It